• Business Incubator,
  • Manufacturing,

HERA-MI: Artificial Intelligence for early stage breast cancer diagnosis

Published on January 9, 2020 Updated on January 24, 2020
Hera-MI aims to use Artificial Intelligence (AI) to help early-stage breast cancer diagnosis in order to optimize patient care and save millions of women's lives worldwide. Its ambition is to speed up and improve breast cancer diagnosis thanks to the development of clinical decision support solutions. Hera-MI has developed Breast-SlimView, a patented clinical decision support solution for 2D/3D mammography.
Over the past few years, the volume of medical images has been constantly expanding. Medical equipment now generates 1,000 to 1,500 images per medical exam, which is 40 times more than 30 years ago. Radiologists are now dealing with about 50,000 images a day. However, processing such data volumes is now stretching the capacity of the human brain to the point of becoming risky. Buried beneath a huge amount of data, the radiologist's ability to diagnose is negatively affected by intense stress and fatigue combined with the fear of being mistaken. 3D mammography (Digital Breast Tomosynthesis) has drastically increased the volume of images as well as the amount of information radiologists must review.

In this context, HERA-MI's main goal is to use AI to help promote the early diagnosis of breast cancer. AI can analyze a huge quantity of data in a very short time and help radiologists detect anomalies that can be sometimes hard to see.

HERA-Mi's Chief Scientific Officer is a Centrale Nantes alumni who is also carrying out a CIFRE PhD thesis in Artificial Intelligence applied to medical imaging in the Centrale Nantes LS2N laboratory (Laboratory of Digital Sciences of Nantes).

Published on January 9, 2020 Updated on January 24, 2020